SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+10.95%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$360M
AUM Growth
+$360M
(+91%)
Cap. Flow
+$112M
Cap. Flow
% of AUM
31.22%
Top 10 Holdings %
Top 10 Hldgs %
61.27%
Holding
86
New
21
Increased
12
Reduced
26
Closed
20
Top Buys
| 1 |
BioAtla
BCAB
|
$108M |
| 2 |
Galecto
GLTO
|
$18.9M |
| 3 |
NVTA
Invitae Corporation
NVTA
|
$10.2M |
| 4 |
C4 Therapeutics
CCCC
|
$8.9M |
| 5 |
Exelixis
EXEL
|
$7.84M |
Top Sells
| 1 |
OraSure Technologies
OSUR
|
$7.61M |
| 2 |
QuidelOrtho
QDEL
|
$6.75M |
| 3 |
IMMU
Immunomedics Inc
IMMU
|
$6.49M |
| 4 |
Sarepta Therapeutics
SRPT
|
$6.48M |
| 5 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$6.35M |
Sector Composition
| 1 | Healthcare | 90.41% |
| 2 | Consumer Staples | 2.45% |
| 3 | Real Estate | 0.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
BioAtla
BCAB
$26.7M
| $108M | 14.27% | +3,179,362 | New | +$108M |
|
2
ESSA Pharma
EPIX
$11.4M
| $28.3M | 3.74% | 2,375,681 +548,701 | +30% | +$6.55M |
|
|
3
Galecto
GLTO
$4.21M
| $18.9M | 2.5% | +1,512,648 | New | +$18.9M |
|
|
ISEE
4
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $11M | 1.46% | 1,597,279 -88,600 | -5% | -$612K |
|
|
NVTA
5
DELISTED
Invitae Corporation
NVTA
| $10.2M | 1.35% | +244,760 | New | +$10.2M |
|
6
Lantheus
LNTH
$3.73B
| $10M | 1.32% | 742,085 +232,541 | +46% | +$3.14M |
|
|
7
C4 Therapeutics
CCCC
$185M
| $8.9M | 1.17% | +268,548 | New | +$8.9M |
|
8
Xenon Pharmaceuticals
XENE
$2.98B
| $8.58M | 1.13% | 558,117 +57,853 | +12% | +$890K |
|
|
9
Exelixis
EXEL
$10.1B
| $7.84M | 1.04% | +390,847 | New | +$7.84M |
|
10
Natera
NTRA
$23.1B
| $7.38M | 0.97% | 74,189 -26,900 | -27% | -$2.68M |
|
11
Vericel Corp
VCEL
$1.83B
| $7.31M | 0.96% | 236,589 -116,417 | -33% | -$3.59M |
|
|
INBX
12
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $7.05M | 0.93% | 213,807 -192,693 | -47% | -$6.35M |
|
13
iRadimed
IRMD
$921M
| $6.93M | 0.91% | 303,998 +105,259 | +53% | +$2.4M |
|
|
TCRR
14
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $6.18M | 0.82% | 199,867 -82,174 | -29% | -$2.54M |
|
15
DarioHealth
DRIO
$22.8M
| $5.74M | 0.76% | +401,606 | New | +$5.74M |
|
16
Mersana Therapeutics
MRSN
$36.5M
| $5.5M | 0.73% | 206,844 -186,197 | -47% | -$4.95M |
|
17
Lyra Therapeutics
LYRA
$11.5M
| $5.2M | 0.69% | 456,138 +345,468 | +312% | +$3.94M |
|
18
ARS Pharmaceuticals
SPRY
$1.15B
| $5M | 0.66% | +107,826 | New | +$5M |
|
19
The Beauty Health Co
SKIN
$264M
| $4.71M | 0.62% | +416,551 | New | +$4.71M |
|
20
NovoCure
NVCR
$1.38B
| $4.33M | 0.57% | 24,999 -27,378 | -52% | -$4.74M |
|
21
Hims & Hers Health
HIMS
$9.57B
| $4.11M | 0.54% | +281,565 | New | +$4.11M |
|
22
Surmodics
SRDX
$487M
| $4.05M | 0.53% | 92,975 +15,692 | +20% | +$683K |
|
|
MSON
23
DELISTED
Misonix Inc
MSON
| $3.77M | 0.5% | 301,333 +51,080 | +20% | +$639K |
|
24
AstraZeneca
AZN
$248B
| $3.21M | 0.42% | 64,284 +55,081 | +599% | +$2.75M |
|
25
DexCom
DXCM
$29.5B
| $3.02M | 0.4% | 8,165 +582 | +8% | +$215K |
|